Search

ViiV Healthcare premieres early data showing antiviral activity against integrase resistance from its investigational, third-generation integrase inhibitor

Data, along with results from a phase I study, are the first public presentation of VH4524184.

First published: 23 July 2024

Antiviral activity of S/GSK1349572, the only once-daily, unboosted integrase inhibitor in clinical development, evaluated in phase 2 study

GSK announced results from Phase 2a study evaluating antiviral activity of INI, S/GSK1349572, results presented at IAS Conference.

First published: 20 July 2009

Antiviral Activity of S/GSK1265744, a Once-Daily, Unboosted Integrase Inhibitor in Clinical Development, Evaluated in Phase 1-2a Study in Healthy and HIV-Infected Subjects

GSK announced results from Phase 1-2a study evaluating PK, safety and activity of its INI S/GSK1265744 in healthy HIV-infected patients.

First published: 13 September 2009

ViiV Healthcare presents positive proof-of-concept findings for N6LS, an investigational, broadly neutralising antibody (bNAb) offering a potential new approach for the treatment of HIV

Data from the BANNER study show antiviral efficacy, safety, and tolerability of N6LS, supporting its continued study in phase IIb

First published: 25 October 2022

The UK Government signs influenza pandemic contract with GlaxoSmithKline for Relenza®

The UK is now one of the leading countries in stockpiling antivirals for treating infected individuals in event of an influenza pandemic

First published: 28 January 2009

Understanding our value chain water footprint

First published: 18 March 2025

CROI Proof Of Concept Studies Press Release

First published: 10 March 2025

Press Release AIDS 2024 VH184

First published: 05 December 2024

GSK Receives US FDA Fast Track Designation For Bepirovirsen Press Release

First published: 05 December 2024

Press Release Agreement To Obtain Exclusive License For JNJ 3989 31 Oct 2023

First published: 06 December 2024